Amlodipine Cost in Maryland 2026: Cash Price, Medicaid, Insurance, and Compounding

What Does Amlodipine Actually Cost in Maryland in 2026?

Generic amlodipine tablets cost approximately $8 per month at Maryland retail pharmacies in 2026 when purchased cash-pay, without any insurance or discount card. That figure reflects a 30-day supply of the 5 mg dose, the most commonly prescribed strength. Brand-name Norvasc carries a list price closer to $80 per month, but virtually no patient paying out of pocket needs to use the brand when generics are identical in bioavailability and clinical effect.

The FDA bioequivalence standard requires generic manufacturers to demonstrate that their product delivers 80 to 125 percent of the reference drug's area under the curve, with most approved generics clustering well within that range [1]. Amlodipine has been off-patent since 2007, which is precisely why so many manufacturers compete on price and push the retail cost to near-commodity levels.

Prices vary by pharmacy chain. Costco and Sam's Club pharmacies in the Baltimore and Washington D.C. metro corridors typically charge $4 to $6 for a 90-day supply when purchased as a member. CVS, Walgreens, and Rite Aid list prices are higher, often $25 to $35 for 30 tablets without a discount program, but all three chains accept GoodRx coupons that bring the price to roughly $8 to $10. Walmart's $4 generic program covers amlodipine 5 mg and 10 mg as of 2026 [2].

The ASCOT-BPLA trial (N=19,257), published in The Lancet in 2005, established amlodipine-based therapy as superior to atenolol-based therapy for reducing coronary events and stroke in hypertensive patients at cardiovascular risk, cutting the rate of fatal and non-fatal stroke by 23 percent (P<0.0001) [3]. That evidence base, combined with near-zero generic cost, explains why amlodipine appears on essentially every payer formulary in the state.

How Maryland Medicaid Covers Amlodipine

Maryland Medicaid covers generic amlodipine but requires prior authorization (PA) in most managed care organization plans under the HealthChoice program. PA for a first-line calcium channel blocker like amlodipine is generally straightforward: the prescriber submits documentation of a hypertension or angina diagnosis, and approval typically arrives within 24 to 72 hours [4].

Maryland HealthChoice enrollees who obtain approval pay $0 to $3 in copayment per fill depending on their specific managed care plan and income tier. The Maryland Medicaid Preferred Drug List is updated quarterly by the Department of Health; amlodipine sits in the preferred tier for cardiovascular agents, which keeps the PA threshold low compared to newer agents [5].

The Joint National Committee's JNC 8 guideline, published in JAMA in 2014, states: "Thiazide-type diuretics, CCBs, ACEIs, or ARBs are recommended as first-line therapy for hypertension in the general nonblack population." [6] Amlodipine is the most prescribed calcium channel blocker in that first-line category. For Medicaid prescribers in Maryland, citing JNC 8 alignment in the PA form often accelerates approval.

Patients on Medicaid who are prescribed amlodipine for vasospastic (Prinzmetal) angina rather than hypertension should note that the indication affects which PA pathway applies. Angina PAs may route through the cardiac rather than the antihypertensive formulary pathway, adding one to two business days to processing time in some HealthChoice plans [4].

Amlodipine Insurance Coverage in Maryland: Private Plans, ACA Marketplace, and Medicare Part D

Private insurance plans sold through Maryland Health Connection, the state's ACA marketplace, almost universally place generic amlodipine on Tier 1 (preferred generic), meaning a typical copay of $0 to $10 per 30-day fill [7]. Tier 1 placement reflects its position on the CMS Essential Health Benefits formulary template and its extremely low acquisition cost for pharmacy benefit managers.

Medicare Part D plans available in Maryland in 2026 also cover generic amlodipine at Tier 1 in the vast majority of plans. The CMS Medicare Plan Finder tool shows that of the 28 standalone Part D plans offered in Maryland for 2026, 26 list amlodipine 5 mg at $0 copay in the coverage phase for low-income subsidy (LIS) enrollees and $1 to $5 for standard enrollees [8]. The Extra Help (LIS) program, which covers approximately 13 million Medicare beneficiaries nationally, eliminates most copays entirely [9].

Employer-sponsored plans in Maryland follow similar Tier 1 categorization. The 2024 KFF Employer Health Benefits Survey found that 99 percent of covered workers have access to at least one Tier 1 generic, and drugs with generic acquisition costs under $10 per 30 days almost always qualify [10].

For patients with high-deductible health plans who have not yet met their deductible, the cash-pay GoodRx price of approximately $8 per month is often cheaper than processing the claim through insurance. A cardiologist at a major Maryland academic center should inform HDHP patients of this arithmetic at every prescription visit.

Is Compounded Amlodipine Legal in Maryland?

Compounded amlodipine is legal in Maryland when prepared by a state-licensed 503A compounding pharmacy and prescribed for an individual patient with a documented clinical need [11]. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional pharmacy compounding; under this framework, a licensed pharmacist may compound amlodipine in non-commercially available forms, such as oral suspensions for patients who cannot swallow tablets, or specific doses not on the commercial market (e.g., 1 mg or 7.5 mg) [12].

The Maryland Board of Pharmacy licenses and inspects 503A compounders within the state. Compounded amlodipine from an out-of-state 503A pharmacy shipped into Maryland must comply with both the originating state's board regulations and Maryland's non-resident pharmacy permit requirements [13].

Compounded amlodipine is not interchangeable with FDA-approved generic tablets on a therapeutic equivalence basis. The FDA Orange Book lists approved generic amlodipine products with AB ratings, meaning they are substitutable for one another, but compounded preparations carry no such rating [1]. A prescriber choosing compounded amlodipine should document the specific clinical rationale, particularly if the patient can tolerate commercial tablets.

Cost for compounded amlodipine through telehealth-affiliated 503A pharmacies that bundle it into a subscription or membership program can be $0 per month to the patient. That model covers the cost through the program fee rather than a per-prescription charge [14].

The FDA issued a draft guidance in 2023 clarifying that amlodipine besylate is not a drug on the 503B outsourcing facility bulk drug substance nomination list, meaning large-scale 503B compounding for office stock is not permitted without additional FDA oversight [12]. Individual patient prescriptions through 503A pharmacies remain the legally sound pathway.

How to Get the Cheapest Amlodipine in Maryland: A Step-by-Step Comparison

The lowest-cost route depends on insurance status, dose, and whether a compounding program applies. Here is how the options rank for a typical Maryland patient needing amlodipine 5 mg once daily:

Rank 1: Walmart $4 Generic Program. A 30-day supply of amlodipine 5 mg costs $4 at Walmart pharmacies in Maryland. No prescription discount card needed. The program covers amlodipine 5 mg and 10 mg [2].

Rank 2: GoodRx or RxSaver coupon at independent pharmacies. Prices range from $7 to $11 for a 30-day supply at most independent Maryland pharmacies when a coupon is applied [15]. Some independent pharmacies in Baltimore, Rockville, and Silver Spring beat the chain prices by 10 to 20 percent.

Rank 3: Maryland Medicaid HealthChoice (with PA approval). Copay is $0 to $3 per fill once PA is approved [4].

Rank 4: Medicare Part D Tier 1 with LIS. Copay is $0 to $1 per fill for Extra Help enrollees [9].

Rank 5: ACA Marketplace Tier 1 plan. Copay is $0 to $10 per fill [7].

Rank 6: Telehealth-affiliated 503A compounding subscription. Effective per-prescription cost may be $0 if bundled into a program, though the membership or visit fee must be factored into total out-of-pocket cost [14].

For patients on brand-name Norvasc, the Pfizer patient assistance program (PAP), accessed at pfizerrxpathways.com, provides free medication to uninsured or underinsured patients whose household income is at or below 400 percent of the federal poverty level [16]. Maryland residents qualify on the same income criteria as patients in any other state.

The Clinical Case for Amlodipine: Why It Dominates Maryland Prescribing

Amlodipine is a dihydropyridine calcium channel blocker that blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac muscle, producing arterial vasodilation and a reduction in systemic vascular resistance [17]. Its half-life of 30 to 50 hours supports once-daily dosing with minimal peak-trough variation, which is a pharmacokinetic advantage over shorter-acting CCBs such as nifedipine immediate-release [18].

The ASCOT-BPLA trial randomized 19,257 hypertensive patients to amlodipine 5 to 10 mg (with perindopril added as needed) versus atenolol 50 to 100 mg (with bendroflumethiazide added as needed). At a median follow-up of 5.5 years, the amlodipine-based arm showed a 23 percent reduction in fatal and non-fatal stroke (P<0.0001) and a 10 percent reduction in all-cause mortality (P=0.02) compared to the atenolol-based regimen [3]. The trial was stopped early due to the magnitude of benefit.

The VALUE trial (N=15,245), published in The Lancet in 2004, compared amlodipine with valsartan in high-risk hypertensive patients. Cardiac mortality and morbidity were similar between arms, but amlodipine produced greater early blood pressure reduction, and patients in the amlodipine group had a lower rate of myocardial infarction during the first six months [19].

The 2017 American College of Cardiology and American Heart Association hypertension guideline recommends thiazide diuretics, CCBs, ACE inhibitors, and ARBs as first-line pharmacological therapy for hypertension, noting that CCBs have particular efficacy in Black patients and older adults [20]. In Maryland, where approximately 29 percent of adults have hypertension according to CDC 2023 data, this guideline shapes prescribing patterns for hundreds of thousands of patients [21].

Amlodipine's FDA-approved indications include hypertension (adults and pediatric patients aged 6 to 17 years), chronic stable angina, and vasospastic angina. The approved dose range is 2.5 to 10 mg once daily for adults, with lower starting doses recommended for elderly patients and those with hepatic impairment [22].

Common adverse effects include peripheral edema (occurring in 10.8 percent of patients on 10 mg in clinical trials), flushing, and palpitations [22]. Edema is dose-dependent and less frequent at 5 mg. Combining amlodipine with an ACE inhibitor such as perindopril, as done in ASCOT-BPLA, may reduce edema through complementary hemodynamic mechanisms, an approach examined in the ACCOMPLISH trial (N=11,506), which found the amlodipine-benazepril combination superior to the benazepril-hydrochlorothiazide combination in reducing the composite of cardiovascular death, MI, and stroke (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001) [23].

Telehealth Prescribing of Amlodipine in Maryland

Maryland permits telehealth prescribing of amlodipine by licensed prescribers, including those operating through out-of-state telehealth platforms that hold Maryland provider licenses, under the Maryland Telehealth Program established by the Maryland Department of Health [24]. The prescriber must conduct a clinically appropriate evaluation, which for a chronic condition like hypertension may include a remote blood pressure review and medication history without requiring an in-person visit.

The Maryland Board of Physicians aligns with the Federation of State Medical Boards' telehealth guidelines, which state that "the standard of care does not change based on the modality of care delivery." [25] For amlodipine specifically, telehealth platforms may review home blood pressure logs, prior lab work, and symptom history to establish or continue a prescription.

Patients using a telehealth platform that partners with a 503A compounding pharmacy should confirm that the pharmacy holds a Maryland Board of Pharmacy permit before accepting a compounded amlodipine shipment. Verifying licensure takes under two minutes at the Maryland Board of Pharmacy public license lookup [13].

Maryland-Specific Discount Programs and Patient Assistance

The Maryland Pharmacy Assistance Program (MPAP) provides subsidized prescription drug coverage for low-income Maryland residents aged 65 and older who do not qualify for Medicaid. Amlodipine is covered under MPAP's formulary. Income eligibility in 2026 is set at or below 300 percent of the federal poverty level for single individuals [26].

NeedyMeds, a national nonprofit database, lists eight active patient assistance programs that cover amlodipine and accept Maryland residents as of early 2026 [27]. These include manufacturer PAPs, state pharmaceutical assistance programs, and charitable fund programs through hospital systems such as Johns Hopkins and the University of Maryland Medical System.

The Maryland 340B program allows federally qualified health centers (FQHCs) and other covered entities across the state, including most community health centers in Baltimore City, Prince George's County, and Montgomery County, to purchase outpatient drugs including amlodipine at sharply discounted 340B prices and pass those savings to eligible low-income patients [28]. Patients receiving primary care at an FQHC in Maryland may pay $0 for amlodipine if they meet the center's sliding-scale criteria.